11 results on '"Ilan, Yaron"'
Search Results
2. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis
- Author
-
Ilan, Yaron, primary
- Published
- 2012
- Full Text
- View/download PDF
3. Point-of-care continuous13C-methacetin breath test improves decision making in acute liver disease: Results of a pilot clinical trial
- Author
-
Lalazar, Gadi, primary, Adar, Tomer, additional, and Ilan, Yaron, additional
- Published
- 2009
- Full Text
- View/download PDF
4. Intrahepatic CD8+ lymphocyte trapping during tolerance induction using mushroom derived formulations: A possible role for liver in tolerance induction
- Author
-
Shuvy, Mony, primary, Hershcovici, Tiberiu, additional, Lull-Noguera, Cristina, additional, Wichers, Harry, additional, Danay, Ofer, additional, Levanon, Dan, additional, Zolotarov, Lidya, additional, and Ilan, Yaron, additional
- Published
- 2008
- Full Text
- View/download PDF
5. Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.
- Author
-
Khoury T, Ben Ya'acov A, Shabat Y, Zolotarovya L, Snir R, and Ilan Y
- Subjects
- Administration, Oral, Animals, Biomarkers blood, Blood Glucose drug effects, Blood Glucose metabolism, Chemical and Drug Induced Liver Injury blood, Chemical and Drug Induced Liver Injury immunology, Chemical and Drug Induced Liver Injury pathology, Choline Deficiency complications, Concanavalin A, Cytoprotection, Diet, High-Fat, Disease Models, Animal, Insulin blood, Lipids blood, Liver immunology, Liver metabolism, Liver pathology, Metabolic Syndrome immunology, Metabolic Syndrome prevention & control, Methionine deficiency, Mice, Non-alcoholic Fatty Liver Disease blood, Non-alcoholic Fatty Liver Disease immunology, Non-alcoholic Fatty Liver Disease pathology, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Time Factors, Tumor Necrosis Factor-alpha blood, Chemical and Drug Induced Liver Injury prevention & control, Immunologic Factors administration & dosage, Insulin Resistance, Liver drug effects, Non-alcoholic Fatty Liver Disease prevention & control, Plant Extracts administration & dosage, Glycine max, T-Lymphocytes, Regulatory drug effects
- Abstract
Aim: To determine the immune-modulatory and the hepatoprotective effects of oral administration of two soy extracts in immune mediated liver injury and non-alcoholic steatohepatitis (NASH)., Methods: Two soy extracts, M1 and OS, were orally administered to mice with concanavalin A (ConA) immune-mediated hepatitis, to high-fat diet (HFD) mice and to methionine and choline reduced diet combined with HFD mice. Animals were followed for disease and immune biomarkers., Results: Oral administration of OS and M1 had an additive effect in alleviating ConA hepatitis manifested by a decrease in alanine aminotransferase and aspartate aminotransferase serum levels. Oral administration of the OS and M1 soy derived fractions, ameliorated liver injury in the high fat diet model of NASH, manifested by a decrease in hepatic triglyceride levels, improvement in liver histology, decreased serum cholesterol and triglycerides and improved insulin resistance. In the methionine and choline reduced diet combined with the high fat diet model, we noted a decrease in hepatic triglycerides and improvement in blood glucose levels and liver histology. The effects were associated with reduced serum tumor necrosis factor alpha and alteration of regulatory T cell distribution., Conclusion: Oral administration of the combination of OS and M1 soy derived extracts exerted an adjuvant effect in the gut-immune system, altering the distribution of regulatory T cells, and alleviating immune mediated liver injury, hyperlipidemia and insulin resistance.
- Published
- 2015
- Full Text
- View/download PDF
6. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.
- Author
-
Israeli E, Zigmond E, Lalazar G, Klein A, Hemed N, Goldin E, and Ilan Y
- Subjects
- Administration, Oral, Adult, Cell Separation methods, Colon immunology, Colon metabolism, Crohn Disease diagnosis, Crohn Disease immunology, Crohn Disease metabolism, Double-Blind Method, Female, Flow Cytometry, Humans, Immune Tolerance drug effects, Immunity, Mucosal drug effects, Israel, Male, Middle Aged, Proteins immunology, Proteins isolation & purification, Remission Induction, Severity of Illness Index, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets immunology, Time Factors, Treatment Outcome, Young Adult, Colon drug effects, Crohn Disease therapy, Desensitization, Immunologic methods, Proteins administration & dosage
- Abstract
Aim: To evaluate the safety and efficacy of oral administration of Alequel™, an autologous protein-containing colon extract., Methods: A total of 43 patients were enrolled in a randomized, placebo-controlled, double-blind trial. Patients were orally administered with autologous protein-containing colon extract three doses of autologous study drug per week for 15 wk, for a total of 45 doses. Patients were followed for safety parameters. Remission was defined as a Crohn's disease activity index (CDAI) score of less than or equal to 150. All patients were followed for changes in subsets of T cells by fluorescence-activated cell sorting analysis., Results: Analysis was performed on a total number of evaluable patients of 14 in the study drug group and 15 in the placebo group. Treatment was well tolerated by all patients. No major treatment-related adverse events were reported or observed in any of the treated patients during the feeding or follow-up periods. Between weeks 6 and 9 of the study, six of the 14 (43%) evaluable subjects who received the study drug achieved a CDAI of 150 or lower. In contrast, five of the 15 (33%) evaluable subjects in the placebo group achieved remission. Between weeks 9 and 12, the remission rates were 50% and 33% for the drug group and placebo group, respectively. Among the drug-treated subjects who achieved remission, the effect of the drug was judged as stable in eight of the 14 subjects as measured by at least two CDAI scores indicating remission in the 15-wk treatment period. A decreased percentage of peripheral natural killer T regulatory cells (a decrease of 28% vs an increase of 16%) and an increased ratio of CD4(+)/CD8(+) T lymphocytes (an increase of 11% vs a decrease of 9%) were noted in subjects with a significant clinical response., Conclusion: Oral administration of the autologous colonic extract could be a safe and effective for the treatment of patients with moderate to severe Crohn's disease.
- Published
- 2015
- Full Text
- View/download PDF
7. Gastric stimulation for weight loss.
- Author
-
Mizrahi M, Ben Ya'acov A, and Ilan Y
- Subjects
- Appetite physiology, Gastrointestinal Hormones physiology, Humans, Intestines physiology, Satiation physiology, Vagus Nerve physiology, Electric Stimulation Therapy methods, Gastrointestinal Motility physiology, Obesity therapy, Stomach physiology, Weight Loss
- Abstract
The prevalence of obesity is growing to epidemic proportions, and there is clearly a need for minimally invasive therapies with few adverse effects that allow for sustained weight loss. Behavior and lifestyle therapy are safe treatments for obesity in the short term, but the durability of the weight loss is limited. Although promising obesity drugs are in development, the currently available drugs lack efficacy or have unacceptable side effects. Surgery leads to long-term weight loss, but it is associated with morbidity and mortality. Gastric electrical stimulation (GES) has received increasing attention as a potential tool for treating obesity and gastrointestinal dysmotility disorders. GES is a promising, minimally invasive, safe, and effective method for treating obesity. External gastric pacing is aimed at alteration of the motility of the gastrointestinal tract in a way that will alter absorption due to alteration of transit time. In addition, data from animal models and preliminary data from human trials suggest a role for the gut-brain axis in the mechanism of GES. This may involve alteration of secretion of hormones associated with hunger or satiety. Patient selection for gastric stimulation therapy seems to be an important determinant of the treatment's outcome. Here, we review the current status, potential mechanisms of action, and possible future applications of gastric stimulation for obesity.
- Published
- 2012
- Full Text
- View/download PDF
8. Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.
- Author
-
Lalazar G, Adar T, and Ilan Y
- Subjects
- Acute Disease, Adolescent, Adult, Carbon Isotopes analysis, Female, Hepatitis diagnosis, Hepatitis B diagnosis, Hepatolenticular Degeneration diagnosis, Humans, Israel, Liver injuries, Liver Function Tests, Male, Patient Selection, Pilot Projects, Point-of-Care Systems, Pregnancy, Pregnancy Complications diagnosis, Reference Values, Young Adult, Acetamides analysis, Breath Tests methods, Liver Diseases diagnosis
- Abstract
Aim: To assess the role of the (13)C-methacetin breath test (MBT) in patients with acute liver disease., Methods: Fifteen patients with severe acute liver disease from diverse etiologies were followed-up with (13)C-MBT during the acute phase of their illnesses (range 3-116 d after treatment). Patients fasted for 8 h and ingested 75 mg of methacetin prior to the MBT. We compared results from standard clinical assessment, serum liver enzymes, synthetic function, and breath test scores., Results: Thirteen patients recovered and two patients died. In patients that recovered, MBT parameters improved in parallel with improvements in lab results. Evidence of consistent improvement began on day 3 for MBT parameters and between days 7 and 9 for blood tests. Later convergence to normality occurred at an average of 9 d for MBT parameters and from 13 to 28 d for blood tests. In both patients that died, MBT parameters remained low despite fluctuating laboratory values., Conclusion: The (13)C-MBT provides a rapid, non-invasive assessment of liver function in acute severe liver disease of diverse etiologies. The results of this pilot clinical trial suggest that the MBT may offer greater sensitivity than standard clinical tests for managing patients with severe acute liver disease.
- Published
- 2009
- Full Text
- View/download PDF
9. Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.
- Author
-
El Haj M, Ben Ya'acov A, Lalazar G, and Ilan Y
- Subjects
- Animals, Glucosylceramides immunology, Glucosylceramides therapeutic use, Glycolipids immunology, Glycolipids therapeutic use, Humans, Killer Cells, Natural immunology, Ligands, Mice, Colitis immunology, Colitis therapy, Killer Cells, Natural physiology
- Abstract
Natural killer T lymphocytes (NKT) have been implicated in the regulation of autoimmune processes in both mice and humans. In response to stimuli, this subset of cells rapidly produces large amounts of cytokines thereby provoking immune responses, including protection against autoimmune diseases. NKT cells are present in all lymphoid compartments, but are most abundant in the liver and bone marrow. They are activated by interaction of their T-cell receptor with glycolipids presented by CD1d, a nonpolymorphic, major histocompatibility complex class I-like molecule expressed by antigen presenting cells. Several possible ligands for NKT cells have recently been suggested. beta-glucosylceramide, a naturally occurring glycolipid, is a metabolic intermediate in the anabolic and catabolic pathways of complex glycosphingolipids. Like other beta-glycolipids, beta-glucosylceramide has an immunomodulatory effect in several immune mediated disorders, including immune mediated colitis. Due to the broad impact that NKT cells have on the immune system, there is intense interest in understanding how NKT cells are stimulated and the extent to which NKT cell responses can be controlled. These novel ligands are currently being evaluated in animal models of colitis. Here, we discuss strategies to alter NKT lymphocyte function in various settings and the potential clinical applications of natural glycolipids.
- Published
- 2007
- Full Text
- View/download PDF
10. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial.
- Author
-
Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, and Ilan Y
- Subjects
- Administration, Oral, Adult, Aged, Alanine Transaminase metabolism, Antioxidants administration & dosage, Antioxidants adverse effects, Aspartate Aminotransferases metabolism, Biopsy, Double-Blind Method, Female, Hepacivirus genetics, Hepatitis C, Chronic enzymology, Hepatitis C, Chronic pathology, Humans, Injections, Intravenous, Liver enzymology, Liver pathology, Male, Middle Aged, RNA, Viral blood, Antioxidants therapeutic use, Hepatitis C, Chronic drug therapy, Interferons
- Abstract
Aim: To assess the safety and efficacy of antioxidant therapy for patients with chronic hepatitis C virus (HCV) infection., Methods: One hundred chronic HCV infection patients failed in interferon treatment were enrolled and randomly assigned to receive combined intravenous and oral antioxidants or placebo, or oral treatment alone. Primary end points were liver enzymes, HCV-RNA levels and histology., Results: Combined oral and intravenous antioxidant therapy was associated with a significant decline in ALT levels in 52% of patients who received antioxidant therapy vs 20% of patients who received placebo (P = 0.05). Histology activity index (HAI) score at the end of treatment was reduced in 48% of patients who received antioxidant therapy vs 26% of patients who received placebo (P = 0.21). HCV-RNA levels decreased by 1-log or more in 28% of patients who received antioxidant therapy vs 12% who received placebo (P = NS). In part II of the trial, oral administration of antioxidants was not associated with significant alterations in any of the end points., Conclusion: Antioxidant therapy has a mild beneficial effect on the inflammatory response of chronic HCV infection patients who are non-responders to interferon. Combined antiviral and antioxidant therapy may be beneficial for these patients.
- Published
- 2007
- Full Text
- View/download PDF
11. Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.
- Author
-
Israeli E, Goldin E, Shibolet O, Klein A, Hemed N, Engelhardt D, Rabbani E, and Ilan Y
- Subjects
- Administration, Oral, Adult, Colon cytology, Female, Humans, Intestinal Mucosa cytology, Male, Middle Aged, Prospective Studies, Crohn Disease immunology, Crohn Disease therapy, Proteins administration & dosage
- Abstract
Aim: To evaluate safety and possible efficacy of induction of oral immune regulation using colitis extracted proteins (CEP) in Crohn's disease (CD) subjects., Methods: Ten CDs were treated orally with autologous CEP thrice weekly for 16 wk. Subjects were monitored for CDAI and IBDQ. Immune modulatory effect was assessed by T-lymphocyte FACS analysis, CEP-specific IFNgamma ELISPOT assay and cytokine levels., Results: Induction of oral immune regulation significantly ameliorated disease activity. All (10/10) subjects had clinical response (CDAI < or = 70) and 7/10 achieved clinical remission (CDAI < or = 150). Significant increase in mean IBDQ score was noted (134+/-9 vs 164+/-12). No treatment-related adverse events were noted. High levels of CEP-specific IFNgamma spot forming colonies were detected in five subjects prior to treatment and in all five, a marked decrease was observed. The CD4+/CD8+ lymphocyte ratio and peripheral NKT cell numbers increased significantly, in 7/10 and in 5/10 subjects, respectively. Significant increase in serum IL-10 and IL-4 levels was observed in 7/10 subjects during treatment period., Conclusion: Immune regulation via oral administration of CEP is a safe and possibly effective treatment for subjects with moderate CD and may provide means of antigen-specific immune modulation.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.